By Maureen Marino Earlier this week, the HHS doubled down on new vaccine technology. The government granted Maryland-based Novavax a contract worth up to $179.1 million, while Cranbury, NJ’s VaxInnate picked up a potential $196 million deal. Both companies are developing new approaches to seasonal and pandemic influenza that could help the country move away from slower, […]
Immunogenicity and Tolerability of V503 Versus GARDASIL
ClinicalTrials.gov This study is currently recruiting participants. Verified by Sanofi Pasteur MSD, February 2011 First Received: February 24, 2011 No Changes Posted Purpose Primary objective: • To demonstrate that administration of V503 induces non-inferior Geometric Mean Titers (GMTs) (for serum anti-HPV16 and anti-HPV18) compared to GARDASIL. Secondary objectives: To evaluate the tolerability of V503 […]
Protecting One More Girl
Planned documentary explores the dangers of HPV vaccine Honolulu Weekly by Margot Seeto | Mar 2, 2011 “People don’t just fall over dead.” The One More Girl project / Why would two young men make a documentary about women’s health? For brothers Ryan and David Richardson, who live in Honolulu, the personal became the political. […]
Government Backs Futuristic Flu Shots
By Matthew Herper The U.S. government is pledging $215 million — and as much as $375 million — to two biotechnology companies working to pioneer faster, more efficient ways to make vaccines for influenza. As was evident when the outbreak of the H1N1 swine flu swept across the country in 2009, our system for making […]
An Alzheimer’s vaccine in a nasal spray
One in eight Americans will fall prey to Alzheimer’s disease at some point in their life, current statistics say. Because Alzheimer’s is associated with vascular damage in the brain, many of them will succumb through a painful and potentially fatal stroke. But researchers led by Dr. Dan Frenkel of Tel Aviv University’s Department of Neurobiology […]
- « Previous Page
- 1
- …
- 121
- 122
- 123
- 124
- 125
- …
- 199
- Next Page »
